文献速递慢性肾脏病血液净化与透析

肾脏葡萄糖处理生理学及治疗意义

Renal physiology of glucose handling and therapeutic implications.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

本文综述SGLT2抑制剂在2型糖尿病中的研发与应用演变:初期基于降糖获批,后发现其降压、降白蛋白尿、减轻肾小球高压等作用在CKD各期保留,大型心血管结局试验和CREDENCE试验证实独立于血糖的肾脏保护作用。

要点

  • SGLT2抑制剂在CKD 3-5期降糖效应减弱,但钠相关肾脏效应保留。
  • EMPA-REG OUTCOME、CANVAS、DECLARE TIMI-58一致显示硬肾脏终点减少。
  • CREDENCE首次证实白蛋白尿性T2D患者肾脏和心血管获益。

核心结论

  • SGLT2抑制的肾脏保护作用独立于血糖控制,并在CKD各期保留。

研究设计与样本

  • 综述类,检索并汇总SGLT2抑制剂相关的生理学、心血管结局试验及肾脏保护试验证据。

主要发现

  • SGLT2抑制剂降糖效应在CKD 3-5期减弱,CKD 4期丧失。
  • SGLT2抑制剂具有降压、降白蛋白尿和减轻肾小球高压作用,钠相关效应跨CKD分期保留。
  • EMPA-REG OUTCOME、CANVAS、DECLARE TIMI-58显示心血管事件减少并一致减少硬肾脏终点。
  • CREDENCE试验显示白蛋白尿性T2D患者肾脏和心血管获益。

临床怎么用

  • SGLT2抑制剂可用于T2D合并CKD患者的肾脏和心血管保护,不依赖降糖效果。

局限性

  • 非糖尿病CKD和1型糖尿病中的肾脏保护作用尚待正在进行的试验确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The rationale for using sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes (T2D) has evolved over the last decade. Due to the effects on glucosuria and body weight loss, SGLT2 inhibitors were originally approved for glycemic control in T2D. Since glucosuria is attenuated in chronic kidney disease (CKD) Stages 3-5, initial regulatory approval for SGLT2 inhibitor use was limited to patients with T2D and preserved estimated glomerular filtration rate. Over time, however, it has become increasingly apparent that these therapies have a variety of important pharmacodynamic and clinical effects beyond glycemic lowering, including antihypertensive and antialbuminuric properties, and the ability to reduce glomerular hypertension. Importantly, these sodium-related effects are preserved across CKD stages, despite attenuated glycemic effects, which are lost at CKD Stage 4. With the completion of cardiovascular (CV) outcome safety trials-EMPA-REG OUTCOME, CANVAS Program and DECLARE TIMI-58-in addition to reductions in CV events, SGLT2 inhibition consistently reduces hard renal endpoints. Importantly, these CV and renal effects are independent of glycemic control. Subsequent data from the recent CREDENCE trial-the first dedicated renal protection trial with SGLT-2 inhibition-demonstrated renal and CV benefits in albuminuric T2D patients, pivotal results that have expanded the clinical importance of these therapies. Ongoing trials will ultimately determine whether SGLT2 inhibition will have a role in renal protection in other clinical settings, including nondiabetic CKD and type 1 diabetes.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Cherney DZ, Kanbay M, Lovshin JA, et al. Renal physiology of glucose handling and therapeutic implications. Nephrol Dial Transplant. 2020. PMID: 32003835. doi:10.1093/ndt/gfz230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。